

**REMARKS**

**Claim Rejections – 35 USC § 112**

The Examiner has rejected claims 29 and 37 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. Specifically, the Examiner contends that treatment of cancers generally is not considered to be enabled. The Examiner contends that he is not aware of esters that have been successfully used as anticancer agents, and there are no working examples in the application.

Applicants disagree with the Examiner's contention. Applicants have shown in Table 2 of the specification compounds of the claimed invention inhibit proliferation of murine erythroleukemia cell lines. However, without acquiescing the Examiner's rejection, and solely to accelerate allowance of the case, applicants cancel claims 29 and 37.

Applicants request withdrawal of the above rejection and allowance of the case.

If a telephonic communication with the Applicants' representative will advance the prosecution of the instant application, please telephone the representative indicated below. Applicants believe no additional fees are due but the Commissioner is authorized to charge any fees required in connection with this amendment to Merck Deposit Account No. 13-2755.

Respectfully submitted,

By: /Li Su, Reg. # 45,141/

Li Su  
Registration No. 45,141  
Attorney for Applicants

Merck & Co., Inc.  
PO Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-5455

Date: March 1, 2012